AstraZeneca 'ahead of schedule' in development of personalised medicines
This article was originally published in Clinica
Executive Summary
Pharma giant AstraZeneca has highlighted the importance of biomarkers, beating a self-imposed target of having half of the product candidates in its portfolio associated with patient stratification tools by about three years.